Dinavahi S, Chen Y, Punnath K, Berg A, Herlyn M, Foroutan M, et al. Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma. Cancer Immunol Res. 2022;10:757-769 pubmed publisher

Aarsund M, Segers F, Wu Y, Inngjerdingen M. Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18. Cancer Immunol Immunother. 2022;71:2227-2238 pubmed publisher

Van der Meer J, de Jonge P, van der Waart A, Geerlings A, Moonen J, Brummelman J, et al. CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice. Oncoimmunology. 2021;10:1981049 pubmed publisher

Maas R, Hoogstad van Evert J, Van der Meer J, Mekers V, Rezaeifard S, Korman A, et al. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology. 2020;9:1843247 pubmed publisher